585 related articles for article (PubMed ID: 11593334)
21. Preventing vaccinia virus class-I epitopes presentation by HSV-ICP47 enhances the immunogenicity of a TAP-independent cancer vaccine epitope.
Raafat N; Sadowski-Cron C; Mengus C; Heberer M; Spagnoli GC; Zajac P
Int J Cancer; 2012 Sep; 131(5):E659-69. PubMed ID: 22116674
[TBL] [Abstract][Full Text] [Related]
22. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.
Sensi M; Nicolini G; Zanon M; Colombo C; Molla A; Bersani I; Lupetti R; Parmiani G; Anichini A
Cancer Res; 2005 Jan; 65(2):632-40. PubMed ID: 15695408
[TBL] [Abstract][Full Text] [Related]
24. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine.
Dangoor A; Lorigan P; Keilholz U; Schadendorf D; Harris A; Ottensmeier C; Smyth J; Hoffmann K; Anderson R; Cripps M; Schneider J; Hawkins R
Cancer Immunol Immunother; 2010 Jun; 59(6):863-73. PubMed ID: 20043222
[TBL] [Abstract][Full Text] [Related]
25. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules.
Zajac P; Schütz A; Oertli D; Noppen C; Schaefer C; Heberer M; Spagnoli GC; Marti WR
Cancer Res; 1998 Oct; 58(20):4567-71. PubMed ID: 9788602
[TBL] [Abstract][Full Text] [Related]
26. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
[TBL] [Abstract][Full Text] [Related]
27. Selective responsiveness to common gamma chain cytokines in peripheral blood-derived cytotoxic T lymphocytes induced by Melan-A/MART-1(27-35)targeted active specific immunotherapy.
von Holzen U; Adamina M; Bolli M; Weber WP; Zajac P; Groeper C; Reschner A; Feder C; Schumacher R; Marti W; Oertli D; Heberer M; Spagnoli GC
Int J Cancer; 2005 Jun; 115(2):248-55. PubMed ID: 15688403
[TBL] [Abstract][Full Text] [Related]
28. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus.
Butterfield LH; Jilani SM; Chakraborty NG; Bui LA; Ribas A; Dissette VB; Lau R; Gamradt SC; Glaspy JA; McBride WH; Mukherji B; Economou JS
J Immunol; 1998 Nov; 161(10):5607-13. PubMed ID: 9820539
[TBL] [Abstract][Full Text] [Related]
29. Dual recognition of a human cytotoxic T-cell clone for melanoma antigens.
Kubo H; Abe J; Obata F; Nakajima H; Tsunoda M; Ogawa A; Nakayama S; Beck Y; Kohsaka T; Darrow TL; Abdel-Wahab Z; Saida T; Takiguchi M
Cancer Res; 1996 May; 56(10):2368-74. PubMed ID: 8625313
[TBL] [Abstract][Full Text] [Related]
30. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.
Yee C; Gilbert MJ; Riddell SR; Brichard VG; Fefer A; Thompson JA; Boon T; Greenberg PD
J Immunol; 1996 Nov; 157(9):4079-86. PubMed ID: 8892642
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
[TBL] [Abstract][Full Text] [Related]
32. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.
Larrieu P; Ouisse LH; Guilloux Y; Jotereau F; Fonteneau JF
Cancer Immunol Immunother; 2007 Oct; 56(10):1565-75. PubMed ID: 17318652
[TBL] [Abstract][Full Text] [Related]
33. Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
Lopes L; Fletcher K; Ikeda Y; Collins M
Cancer Immunol Immunother; 2006 Aug; 55(8):1011-6. PubMed ID: 16311731
[TBL] [Abstract][Full Text] [Related]
34. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development.
Kittlesen DJ; Thompson LW; Gulden PH; Skipper JC; Colella TA; Shabanowitz J; Hunt DF; Engelhard VH; Slingluff CL
J Immunol; 1998 Mar; 160(5):2099-106. PubMed ID: 9498746
[TBL] [Abstract][Full Text] [Related]
35. Generation of CD8+ and CD4+ T-cell response to dendritic cells genetically engineered to express the MART-1/Melan-A gene.
Pérez-Díez A; Butterfield LH; Li L; Chakraborty NG; Economou JS; Mukherji B
Cancer Res; 1998 Dec; 58(23):5305-9. PubMed ID: 9850054
[TBL] [Abstract][Full Text] [Related]
36. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells.
Tsai V; Southwood S; Sidney J; Sakaguchi K; Kawakami Y; Appella E; Sette A; Celis E
J Immunol; 1997 Feb; 158(4):1796-802. PubMed ID: 9029118
[TBL] [Abstract][Full Text] [Related]
37. Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A.
Jäger E; Höhn H; Karbach J; Momburg F; Castelli C; Knuth A; Seliger B; Maeurer MJ
Int J Cancer; 1999 Jun; 81(6):979-84. PubMed ID: 10362148
[TBL] [Abstract][Full Text] [Related]
38. Attenuated poxviruses expressing a synthetic HIV protein stimulate HLA-A2-restricted cytotoxic T-cell responses.
Didierlaurent A; Ramirez JC; Gherardi M; Zimmerli SC; Graf M; Orbea HA; Pantaleo G; Wagner R; Esteban M; Kraehenbuhl JP; Sirard JC
Vaccine; 2004 Sep; 22(25-26):3395-403. PubMed ID: 15308364
[TBL] [Abstract][Full Text] [Related]
39. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
[TBL] [Abstract][Full Text] [Related]
40. Antigen presentation of a modified tumor-derived peptide by tumor infiltrating lymphocytes.
Dionne SO; Smith MH; Marincola FM; Lake DF
Cell Immunol; 2001 Dec; 214(2):139-44. PubMed ID: 12088412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
